Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

समान संसाधन

• A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer
  द्वारा: Gatti‐Mays, Margaret E., और अन्य
  प्रकाशित: (2020)
• Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
  द्वारा: Lampert, Erika J, और अन्य
  प्रकाशित: (2020)
• Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
  द्वारा: Brill, Ethan, और अन्य
  प्रकाशित: (2017)
• The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
  द्वारा: Parmar, Kalindi, और अन्य
  प्रकाशित: (2019)
• Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study
  द्वारा: Lee, Jung-Min, और अन्य
  प्रकाशित: (2018)